Semaglutide Lowers Blood Pressure, But Not as a Treatment

Semaglutide drops systolic blood pressure by about the amount you’d expect from a mild diuretic, and the effect shows up in randomized, placebo-controlled trials, not just in cohort data you’d have to squint at. That is the real finding. What it is not is a reason to think of semaglutide as a blood pressure drug: most of the drop traces back to weight loss, the one trial built to isolate semaglutide’s own cardiovascular effect never reported a blood pressure number for it, and nobody has tested what happens when you combine it with an existing antihypertensive or a stimulant.

The drop is real, and it’s about the size of a mild diuretic

A pooled individual-patient-data analysis of three large randomized trials, 3,136 participants in total, found systolic blood pressure fell 4.95 mmHg more on semaglutide 2.4 mg than on placebo.^[1] That held up whether or not participants had hypertension at baseline, which argues against the effect being some artifact of a particular subgroup.

4.95 mmHg greater drop in systolic blood pressure with semaglutide than placebo, pooled across three large randomized trials PMID 39217502

What that number is not: semaglutide is not approved or studied as a treatment for hypertension, and no trial has pitted it head-to-head against a standard antihypertensive. A 5 mmHg average drop is useful information about a side effect. It is not a treatment protocol.

What two different trial designs measured

Two separate randomized designs produced two separate pieces of blood pressure evidence, and it’s worth keeping them apart.

• STEP 4 tested continuation versus withdrawal. Participants who had already lost weight on semaglutide during a 20-week run-in were randomized to keep taking the drug or switch to placebo for 48 more weeks. Those who continued saw a 3.9 mmHg greater drop in systolic blood pressure than those switched to placebo (95% CI, -5.8 to -2.0 mmHg), alongside a 9.7 cm greater reduction in waist circumference.^[2]
• SELECT, the cardiovascular outcomes trial, randomized 17,604 adults with established cardiovascular disease and overweight or obesity (no diabetes) to semaglutide or placebo for a mean follow-up of 39.8 months. A primary cardiovascular event, cardiovascular death, nonfatal heart attack, or nonfatal stroke, occurred in 6.5% of the semaglutide group versus 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72-0.90).^[3]

6.5 percent of SELECT's semaglutide group with a cardiovascular death, heart attack, or stroke, versus 8.0 percent on placebo PMID 37952131

Here’s the honest gap: SELECT is the trial you’d most want a blood pressure number from, since it’s the largest and longest semaglutide cardiovascular trial that exists. It isn’t in the published record available for this article. The outcome SELECT was built to answer is hard cardiovascular events. Blood pressure isn’t the number it reports.

Both of these are averages across a study population. They don’t guarantee any individual result. Some trial participants showed no blood pressure change at all, which is the limit of what an average effect across a population can tell any one reader.

Why randomization is what makes a causal claim defensible here

STEP 4 and SELECT both assigned people to semaglutide or placebo by coin flip, more or less. That single design choice is why you can say semaglutide causes the blood pressure difference rather than merely correlates with it. Nobody chose to be in the drug group because they already had better blood pressure control, or worse.

Most peptides people inject never get this kind of evidence. A stack of unregulated compounds gets evaluated through forum testimonials and before-and-after photos, which can’t separate the compound’s effect from everything else happening in that person’s life at the same time. Semaglutide’s blood pressure data clears a bar most of the peptide world never even approaches.

How much of this is just weight loss

Weight loss lowers blood pressure on its own, independent of what caused the weight loss, so semaglutide’s substantial average weight loss in trials is one obvious candidate explanation for the blood pressure drop.

A systematic review and meta-regression of 37 phase 3 trials of GLP-1 receptor agonists and related weight-loss drugs, 50,171 participants in total, put a number on it: weight loss statistically explained about 76% of the variance in systolic blood pressure reduction, equal to a 0.37 mmHg drop for every 1% of body weight lost.^[4]

Systolic blood pressure change vs placebo or comparator

• Semaglutide, pooled: -4.95
• Tirzepatide 5 mg: -4.2
• Tirzepatide 10 mg: -5.34
• Tirzepatide 15 mg: -5.77

Semaglutide figure pooled from three large RCTs; tirzepatide figures from a meta-analysis of seven RCTs by dose.

Bottom line: roughly three-quarters of the blood pressure benefit tracks with how much weight a person lost. The other quarter is unaccounted for by weight alone, and that’s the more interesting, less settled part of the story.

What could explain that remaining quarter? A proposed weight-independent mechanism, demonstrated so far for the related compound liraglutide rather than semaglutide itself, is that GLP-1 receptor agonists can increase the kidney’s excretion of sodium; the same study found this effect could transiently raise blood pressure in patients with severely impaired kidney function, and the authors describe the short-term mechanism as still unclear.^[5]

A natriuretic effect demonstrated in one GLP-1 drug, in a specific and fairly sick population, is not the same thing as a confirmed mechanism for semaglutide in the general population. Nobody has run the equivalent study with semaglutide.

The heart rate question the evidence doesn’t yet answer for semaglutide

Older GLP-1 receptor agonists have a documented habit of nudging resting heart rate up even as they bring blood pressure down, an odd combination, since most things that lower blood pressure either lower heart rate too or leave it alone. A network meta-analysis of 60 trials, published in 2015, found exenatide and liraglutide raised heart rate by roughly 2 to 3.4 beats per minute versus placebo, alongside systolic blood pressure reductions ranging from 1.84 to 4.60 mmHg depending on the comparator.^[6]

Semaglutide hadn’t entered that trial literature yet in 2015. None of the sources available for this article report a semaglutide-specific heart rate number. That’s worth saying plainly rather than assuming the older drugs’ pattern simply carries over: it might, structurally these are close cousins, but “might” is not a citation.

What this means if you take blood pressure medication, or a stimulant

If you’re on an antihypertensive already: a drug that reliably drops systolic pressure by several mmHg, stacked on top of medication doing the same job, is the kind of combination a prescriber should be tracking rather than assuming is harmless by default.

If the Reddit question that prompted this article is yours (“peptides with blood pressure and ADHD meds”), here’s the honest answer: no published trial has tested semaglutide’s blood pressure or heart rate effects specifically in combination with stimulant medications used for ADHD. That is an open question. It hasn’t been documented either way.

What is documented, separately, is that stimulant medications for ADHD already raise blood pressure and heart rate on their own, with no peptide involved. Two drugs that each nudge cardiovascular numbers, taken together, is not a combination to reason about by assumption.

Also worth knowing, if you’re already tracking semaglutide’s side-effect profile: the better-documented trial complaint is gastrointestinal, not cardiovascular, and that data is considerably more complete than anything on blood pressure interactions.

Where semaglutide sits next to tirzepatide

A meta-analysis of seven randomized controlled trials found tirzepatide produces dose-dependent systolic blood pressure reductions of 4.20 mmHg at 5 mg, 5.34 mmHg at 10 mg, and 5.77 mmHg at 15 mg versus comparator, alongside improvements in total cholesterol, LDL, and triglycerides.^[7] That’s the same ballpark as semaglutide’s pooled 4.95 mmHg, maybe a touch larger at the higher doses. It isn’t a different category of effect.

Where semaglutide pulls ahead is scale of hard-outcome evidence: SELECT’s 17,604-patient, multi-year cardiovascular outcomes trial is a bigger and more direct read on heart attacks and strokes than anything tirzepatide has published to match it. If blood pressure is a side effect you’re weighing between the two drugs, the trials say it’s roughly a wash. If you’re weighing which drug’s cardiovascular case is better established on hard outcomes rather than risk factors, semaglutide currently has the larger trial behind it.

None of that makes semaglutide a blood pressure drug. It makes it a weight-loss and cardiovascular-risk drug that happens to move a number doctors care about, mostly for reasons that have nothing to do with the drug itself.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.